JCR Pharmaceuticals Co Ltd (4552.T)
Latest Key Developments (Source: Significant Developments)
June 11 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>::MESOBLAST AND JCR PHARMACEUTICALS EXPAND JAPAN LICENSE AGREEMENT TO USE OF MESENCHYMAL STEM CELLS IN NEWBORNS WITH INSUFFICIENT BLOOD FLOW TO THE BRAIN.MESOBLAST LTD - EXPANDED ITS PARTNERSHIP WITH JCR PHARMACEUTICALS CO. LTD. IN JAPAN.MESOBLAST LTD - DEAL FOR USE OF MESENCHYMAL STEM CELLS (MSCS) FOR TREATMENT OF NEWBORNS WHO LACK SUFFICIENT BLOOD SUPPLY AND OXYGEN TO BRAIN.MESOBLAST LTD - DEAL FOR AGREEMENT HAS NOW BEEN FURTHER EXPANDED TO PROVIDE JCR WITH RIGHTS TO SELL TEMCELL FOR HIE.MESOBLAST LTD - DEAL FOR JCR PLANS TO INITIATE A CLINICAL TRIAL OF TEMCELL IN NEWBORNS WITH HIE IN JULY 2019. Full Article
LONDON AstraZeneca said on Friday JCR Pharma will help make a portion of its potential COVID-19 vaccine in Japan and it will import shots as part of its deal to supply the Asian nation with up 120 million doses from early 2021.